Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Albert Driver

Pulmonary Disease Sellersville, PA Medical Doctor

NPI 1811973803 CMS profile 82619

817 Lawn Ave, Suite 4, Sellersville, PA 18960

Open in the dashboard

General payments

$105,606

399 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Albert Driver of Sellersville, PA is reported in the CMS Open Payments database as having received $105,606 across 399 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $125 1
2022 General $1,004 6
2021 General $45,406 103
2020 General $6,870 86
2019 General $52,200 203

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Albert Driver
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Albert Driver were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Albert Driver Pulmonary Disease median Middle half National median
2019 $52,200 $377 $109–$1,340 $163
2020 $6,870 $230 $56–$907 $114
2021 $45,406 $269 $68–$1,072 $132
2022 $1,004 $390 $100–$1,457 $149
2023 $125 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. GlaxoSmithKline, LLC. $50,585 105 payments
  2. Regeneron Healthcare Solutions, Inc. $33,409 59 payments
  3. Genzyme Corporation $12,619 21 payments
  4. Genentech USA, Inc. $4,828 20 payments
  5. AstraZeneca Pharmaceuticals LP $1,543 58 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $635 28 payments
  7. Sunovion Pharmaceuticals Inc. $380 27 payments
  8. Insmed, Inc. $370 14 payments
  9. Mylan Specialty L.P. $237 14 payments
  10. Grifols USA, LLC $118 6 payments
  11. Other $880 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $78,963 34 payments
  2. Consulting Fee $13,045 4 payments
  3. Food and Beverage $8,612 322 payments
  4. Travel and Lodging $4,960 37 payments
  5. Education $25 2 payments
Products named General payments · program years 2019–2023
  1. DUPIXENT Inflammation And Immunology $33,409 59 payments
  2. TRELEGY ELLIPTA $32,209 52 payments
  3. NUCALA $10,500 25 payments
  4. DUPIXENT Immunology $9,202 16 payments
  5. ANORO $7,687 20 payments
  6. Xolair $4,828 20 payments
  7. DUPIXENT Immunology $3,518 11 payments
  8. BREZTRI $586 8 payments
  9. SPIRIVA RESPIMAT $505 20 payments
  10. LONHALA MAGNAIR $380 27 payments
  11. Other $4,028 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

399 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record